New imaging agent aims to spot tumors and track immunotherapy

NCT ID NCT05629689

Recruiting now Diagnosis Sponsor: GE Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new imaging agent (GEH200520/GEH200521) that lights up on PET scans to help see solid tumors. In Part A, 50 adults with advanced solid tumors will receive the agent and have scans to check safety and how the agent spreads in the body. Part B will see if the agent can show changes in tumors after immunotherapy. The goal is to find a better way to monitor cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEH200520 injection and GEH200521 (18F) injection (imaging agents for PET scans)
What this could lead to: If successful, this could lead to a new way to see tumors on PET scans and track how well immunotherapy is working.
What could go wrong: This is an early Phase 1 trial with only 50 people, so safety and effectiveness are not yet proven. The imaging agent may not clearly show tumors or changes after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMOR ONCOLOGY

Contacts and locations

Locations

Amsterdam UMC
NOT_YET_RECRUITING

Amsterdam, Netherlands
UMC Groningen
RECRUITING

Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.